Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced ...

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

Pfizer's strength lies in its integrated approach to drug development, from discovery to clinical trials, and finally, ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

Pfizer's oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market. It might take a while longer, but Pfizer is on the path to ...

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides ...

Pfizer (PFE) stock hold rating: 2026 patent cliff, falling Covid sales, GLP-1 obesity timeline, and M&A integration risks—read the outlook now.

CNW/ - This World Cancer Day, Pfizer Canada ULC ("Pfizer"), in partnership with leading oncology patient organizations, is ...

BUCHAREST, ROMANIA – Media OutReach Newswire – 6 August 2025 – Pfizer Romania has been officially certified as one of the Best Places to Work in Romania for 2025, a recognition that highlights its ...